Agilent recently announced that it plans to double its manufacturing capacity of therapeutic nucleic acids. The $725 million investment will go toward the Santa Clara, California–based company’s Frederick, Colorado facility. The Colorado plant will get new Train C and D manufacturing lines. The facility already has a Train B manufacturing line, announced in 2020, that…
Baxter may look to sell off BioPharma business
Baxter (NYSE:BAX) today unveiled a strategic roadmap for its future that includes potential plans for its BioPharma Solutions (BPS) business. The company’s plans include a simplified commercial and manufacturing footprint, according to a news release. The company also intends to improve its capital structure. That includes a review of strategic alternatives for its BioPharma Solutions…
Scorpion Biological Services changes name to Scorpius BioManufacturing post-expansion
The contract development and manufacturing organization (CDMO) Scorpion Biological Services will adopt the name Scorpius BioManufacturing after unveiling expanded manufacturing capabilities earlier this year. The company opened a new biomanufacturing facility in San Antonio in October. Scorpius will be headquartered in the same city. A string of companies have also changed their name in 2022. The smoking…
Catalent to invest $40M in biologics facility in Durham, North Carolina
Contract manufacturing giant Catalent has announced that it will set up a new biologics analytical center of excellence in North Carolina’s Research Triangle. The new plant will offer analytical development and testing services for biologics, including cell and gene therapies. Catalent obtained a Job Development Investment Grant (JDIG) from the North Carolina Economic Investment Committee…
Sumitovant Biopharma merges its Enzyvant and Altavant subsidiaries
Enzyvant Therapeutics and Altavant Sciences today announced plans to merge to form a biopharmaceutical company focused on life-altering therapies for people with rare diseases. Through the deal, the combined company will retain the name Enzyvant and will be equipped with a full range of capabilities spanning non-clinical and clinical development and commercialization. It is also…
AstraZeneca sells Ohio manufacturing site to National Resilience
AstraZeneca (LON:AZN) has sold its site in West Chester, Ohio, to National Resilience, a San Diego–headquartered biomanufacturing company. Resilience has agreed to maintain the site’s operations and assets while retaining its employees, including executives. The company will also continue investing in the site’s workforce and facility. Privately-held National Resilience also has separately announced that it…
Healiva buys critical cell therapy manufacturing assets from B. Braun
Healiva announced today that it acquired critical manufacturing assets from B. Braun’s B. Braun Medical AG Switzerland affiliate. The companies declined to disclose financial details for the acquisition. Lugano, Switzerland-based Healiva develops precision medicine for patients with chronic and acute wounds. It acquired a qualified cell bank for the manufacturing of its first cell therapy…
Lilly establishing pharmaceutical manufacturing scholarship program at Purdue
Eli Lilly (NYSE:LLY) announced yesterday that it committed $92.5 million to establish a scholarship program at Purdue University. The funding establishes an innovative new pharmaceutical manufacturing scholarship program. Lilly and Purdue also renewed their strategic research collaboration. This involves a series of moves aimed at expanding their impact in Indiana and improving lives around the…
Aphena Pharma Solutions completes $20M expansion in Tennessee
Aphena Pharma Solutions announced that it completed its $20 million expansion and renovation in Cookeville, Tennessee. The company began its expansion and renovation in mid-2019. It said in a news release that it adds a “large amount” of solid dose packaging capacity. “The expansion added a new 500,000-square-foot facility that is purpose-built for FDA pharmaceutical…
Thermo Fisher grows sales 14% in Q3
Thermo Fisher Scientific posted third-quarter results today that beat the consensus forecast on Wall Street. The company reported profits of $1.5 billion, or $3.79 per share, on sales of $10.7 billion for the three months ended Sept. 30, for a bottom-line loss of 21.3% on sales growth of 14.4% compared with Q3 2021. Adjusted to…